Flight Centre posted improved earnings estimates for FY23 after travel demand regained its pre-pandemic footing. Shares were up by 4.95% today after the announcement, signalling further optimism by investors for a return to regular travel.
By Charlie Ormond,
Counter-drone and electronic warfare supplier Droneshield saw its stock rocket up by 28.3%, trading at 34 cents per share after announcing a significant US $33 million contract with the US Government. This is set to be a back-to-back record year for the Sydney-based company.
By Charlie Ormond,
Ansell shares have fallen by 14.48% today after releasing a trading update forecasting falling sales in FY2024. The company has begun a campaign of business simplification and spending to drive earnings, but shareholders are anxious after seeing the past year’s gains wiped out in a day.
By Charlie Ormond,
Junior biotech Neuren Pharmaceuticals has signed an expanded licensing deal with its US distribution partner Acadia to expand the sale of its drug Daybue to global markets, pushing its stock price up by 16.24% today, trading at $13.53 per share.
By Charlie Ormond,
Alliance Airlines shares soared today, rising by 13.43% after the company announced it has surpassed the top end of its profit guidance by $1.69 million and shared plans for expansion of its fleet of E190s.
By Charlie Ormond,
KMD Brands announced profit guidance of EBITDA between $105–110 million, with record sales surpassing $1 billion, a first for the company. Shares were down by 8.76% despite the positive news as investors remained wary of early signs of poor winter sales.
By Charlie Ormond,
Energy One laid rumours to rest today, announcing it will meet profit guidance for the 2HFY23, with an expected EBITDA of $12.3 million for the entire financial year. Shares were up 5.11% after the news, trading at 19 cents per share.
By Charlie Ormond,
Clinical drug development company Emyria Ltd has announced the beginning of phase 2B recruitment of patients for an MDMA-assisted clinical PTSD trial after Australia recently rescheduled the drug.
By Charlie Ormond,
CSR announced they have entered into an agreement to acquire long-term customer Woven Image for $43 million. The deal will broaden CSR’s range to include acoustic-focused products for commercial environments.
By Charlie Ormond,
Australian Vintage shares jump 10% as the company announces a strategic review to unlock shareholder value. The review will be run by the corporate advisory firm E&P.
By Charlie Ormond,
Investment ideas from the edge of the bell curve.
Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.
All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.
The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.
Fat Tail Daily is brought to you by the team at Fat Tail Investment Research
Copyright © 2026 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988